Scientific deep-dive

Compounded GLP-1s and the Adverse Event Reports

A FAERS study found more adverse event reports for compounded GLP-1s. Reports are voluntary and there is no denominator, but one finding survives that critique: preparation and prescribing errors were reported more often for compounded products, while dosing errors were reported less often.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·2 citations

A pharmacovigilance study of FDA adverse event reports from 2018 to 2024 found that compounded GLP-1 drugs were reported more often than the approved versions for abdominal pain, nausea, diarrhea, gallbladder inflammation and suicidality, with more hospitalizations and more preparation and prescribing errors.[1] Before that means anything, you need to know what a reporting rate is, and why it is not an event rate.

What a FAERS study can and cannot do

The FDA Adverse Event Reporting System collects reports that people volunteer. FDA now lists it as the Adverse Event Monitoring System (AEMS).[2] Nobody is obliged to file one, and nobody counts how many people took the drug in the first place. That second point is the fatal one for interpreting comparisons: without a denominator, you cannot convert reports into a rate.

Now consider what happened to compounded GLP-1s across exactly this window. They were the subject of sustained news coverage, FDA statements, state pharmacy board actions and a national conversation about shortages. Attention drives reporting: clinicians and patients file reports about the things they have been told to worry about.

Nobody counts how many people took the drug, so the reports cannot be converted into a rate.

The authors state the limit plainly: the study was not designed to show a cause-and-effect relationship.[1] In this design that sentence governs everything else.

The finding that survives the critique

One result is far harder to explain away: prescribing and preparation errors were reported more frequently for compounded products.[1] Not every error type moved that way. Dosing and administration errors were reported less often for compounded products than for the approved versions.[1]

Unlike a subjective symptom, which expectation can make people quicker to report, an error is a discrete category of mistake. Preparation and prescribing errors also fit how compounding works: a compounded product usually arrives as a vial at a concentration the pharmacy chose, so it has to be made up correctly and the dose has to be prescribed for that concentration. An approved pen comes premade at a fixed strength.

The FDA has separately reported dosing errors with compounded semaglutide, some requiring hospitalization, from patients and clinicians miscalculating. We covered that in is the vial you received what the label says. This study does not confirm that pattern, since its dosing errors ran lower for compounded products, so those FDA reports stand as their own evidence.

The practical takeaway: if you are using a compounded product drawn from a vial, everything depends on the concentration. Have the dose written in units for your exact concentration, check it against the syringe you are using, and re-check whenever the concentration changes. Our unit converter exists for that.

About the suicidality item

Suicidality appears in the list of more frequently reported effects, and it needs the same caution as everything else here, if anything more. Spontaneous reporting is the weakest form of evidence on any psychiatric outcome, and it is the most susceptible to amplification by news coverage, which this question received a great deal of.

The randomized and regulatory picture is covered in what happened with the suicidality signal, and a large Swedish cohort published this year points the opposite way on mental health outcomes. A FAERS signal does not overturn either, but it is still a reason for the monitoring the authors call for.

What this does not say

  • Not that compounded GLP-1s cause more harm. No rate was measured and no causal design was used.
  • Not that compounded products are equivalent either. Absence of proof runs in both directions, and the quality and dosing variability the authors describe is real.
  • Not a comparison of specific pharmacies. “Compounded” covers everything from a well-run 503B outsourcing facility to the fraudulent labels FDA has documented.
  • Not a reason to stop a treatment you are on without talking to whoever prescribed it.

What the study cannot give you, a pharmacy name can. If you ever need to report a problem or check a concentration, you need to know who made the vial, and some sellers say so up front. Voxy and Rylo Health both name VialsRX of Houston. Oria Meds says its prescriptions may be filled by PerfectRx of Flower Mound, Texas, and TrueMe names CarePoint Infusion Pharmacy.

Others name more than one. TOM Weight Loss, a one-doctor practice for Texas and Utah, sends prescriptions to one of four pharmacies (Drug Crafters, Luxe Med, Cypress and Empower), so ask which one filled yours. HealthHub’s product pages name Redrock Pharmacy and Vios Compounding Pharmacy, while its homepage calls the pharmacy in-house, which is one more reason to read the vial label. Omnia TeleHealth routes compounded versions through Belmar Pharma Solutions, Cabana names Jungle Jim’s Pharmacy, and Midi Health lists Precision Compounding Pharmacy in its terms. A named pharmacy is not a quality rating. It is the detail that makes a report traceable to a product.

Frequently Asked Questions

This study cannot answer that. It found more adverse event reports for compounded products, but reports are voluntary and there is no denominator, since nobody knows how many people took them. The authors state the study was not designed to show cause and effect.
Because attention drives reporting. Compounded GLP-1s were the subject of sustained news coverage, FDA statements and regulatory action across exactly the study period, and people file reports about the things they have been told to worry about.
That prescribing and preparation errors were reported more often for compounded products, while dosing and administration errors were reported less often. Errors are a discrete category of mistake rather than a subjective symptom, and these two fit how compounded drugs are supplied: as vials at a concentration the pharmacy chose, rather than as premade pens.
Spontaneous reporting is the weakest evidence available on psychiatric outcomes and the most easily amplified by news coverage, which this question received a great deal of. The randomized and regulatory picture is set out in our article on what happened with the suicidal ideation signal, and a large Swedish cohort points the opposite way.
That is a conversation with your prescriber rather than a conclusion from this study. What you can do regardless is reduce the risk this study identifies most credibly: make sure your dose is written in units for your exact vial concentration, and re-check it whenever that concentration changes.

References

  1. 1.McCall KL, Mastro Dwyer KA, Casey RT, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Expert Opinion on Drug Safety. 2025. PMID: 40285721.
  2. 2.U.S. Food and Drug Administration FDA Adverse Event Monitoring System (AEMS) [Formerly FDA Adverse Event Reporting System (FAERS)] FDA. 2026. https://www.fda.gov/drugs/surveillance-post-drug-approval-activities/fda-adverse-event-monitoring-system-aems

Thymosin Alpha 1 (Thymalfasin): What the Evidence Shows

Thymosin alpha 1, sold abroad as Zadaxin, is licensed in 30+ countries for hepatitis B but was never FDA-approved. Its largest sepsis trial found no benefit, and FDA's advisers voted 17 to 4 against letting pharmacies compound it.

10 min read

KPV: What the Evidence Shows, and What FDA Found

KPV, a fragment of alpha-MSH, calmed gut inflammation in mouse colitis studies. FDA's 2026 review found no human data. It is not approved or on the 503A bulks list; under an interim HHS policy dated October 2026, HHS does not intend to take enforcement action against topical or oral 503A compounding under strict conditions.

9 min read

5-Amino-1MQ: What the Evidence Shows, and What FDA Has Said

5-amino-1MQ is not a peptide but a small molecule that blocks the enzyme NNMT. Injected into obese mice it caused about 5% weight loss in 11 days. No human study exists, it is on no FDA compounding list, and FDA cited a 503B facility for using it in 2026.

9 min read

PT-141 (Bremelanotide): What the Evidence Shows

PT-141 is bremelanotide, approved as Vyleesi only for low sexual desire in premenopausal women. Its phase 3 trials found small gains in desire and no rise in satisfying sexual events. The men's program stopped in 2007 over blood pressure.

11 min read

AOD-9604: What the Evidence Shows

AOD-9604, a growth hormone fragment, failed its obesity trials: in 536 adults, weight loss beyond placebo was under 1 kg and the developer ended the program in 2007. FDA advisers voted 12 to 0 against compounding it.

9 min read

MOTS-c: What the Evidence Shows, and What FDA Found

MOTS-c slowed weight gain and improved insulin sensitivity in mice. No published trial has given it to people, and there is no established human dose. The 503A bulks list leaves it out; under an interim HHS policy dated October 2026, HHS does not intend to take enforcement action against 503A compounding under strict conditions.

11 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →